Clinical reference Biomarker Directory
Back to directory

Coagulation Factor XII

Established

Factor XII deficiency prolongs lab clotting tests without causing actual bleeding risk.

Also known as FXII Hageman factor
In plain language

Factor XII is unusual: it affects a common blood test (aPTT) but doesn't actually cause bleeding problems. Doctors need to recognize this so they don't mistakenly treat someone for a bleeding risk they don't actually have.

Biomarker & context

Factor XII (Hageman factor) initiates the intrinsic clotting pathway in laboratory testing but is not required for normal blood clotting in the body, making its deficiency a laboratory curiosity more than a clinical bleeding risk.

What it indicates

Factor XII deficiency prolongs the aPTT on lab testing but is generally not associated with abnormal bleeding, an important teaching point since a prolonged aPTT from this cause can be mistakenly worked up as a bleeding risk when it isn't one.

Diagnosis & clinical testing

Diagnosed via specific factor XII assay when an isolated prolonged aPTT is found without any bleeding history; distinguishing factor XII deficiency from a clinically significant deficiency (like factor VIII, IX, or XI) is an important step to avoid unnecessary treatment.

Guiding treatment

No specific treatment is needed for factor XII deficiency itself since it doesn't cause bleeding; separately, factor XII plays a role in some cases of hereditary angioedema (type III, associated with a factor XII gene mutation), a distinct condition requiring its own management.

Clinical significance

An important diagnostic pitfall: prolonged aPTT from this cause should not be mistaken for a bleeding disorder.

References
  1. General coagulation reference literature on factor XII deficiency and hereditary angioedema type III genetics.